Financial PerformanceRecalibration of cost structure has resulted in OpEx reduction of 34% vs. 2023 and maintaining OpEx FY24 guide of $700-$750M, with plans to initiate further reductions.
Market PositionRetail pharmacy contracts finalized with major chains, regional grocers, merchants, buying groups, and independent chains — a total of 17k+ locations vs. FY23.
Regulatory ApprovalsGlobal regulatory approvals for the updated JN.1 COVID vaccine rollout are anticipated over the coming weeks, aligning with early flu vaccine rollout timelines.